Caliber Associates Recruits Chief Medical Officer for NextCure

San Diego, CA- based Caliber Associates recently placed former NexImmune executive Han Myint as the new chief medical officer for NextCure, a clinical-stage biopharmaceutical company. Steve Hochberg, CEO and founder of Caliber Associates, led the assignment. “We are very excited that Han has joined the NextCure team,” said Michael Richman, president and CEO of NextCure. “We believe the depth of his expertise in oncology product development will prove instrumental in the advancement of our product pipeline. Han’s strong industry track record is highlighted by his involvement in the development of multiple U.S. Food and Drug approved products.”

Dr. Myint has over 20 years of experience in both academia and the biopharma industry. Before joining NextCure, he was chief medical officer at NexImmune, a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies. Prior to that, he was vice president of global medical affairs and the myeloid diseases lead at Celgene. Dr. Myint’s work in myeloid diseases at Celgene contributed to a number of FDA approvals, successful launches of those products and high-impact publications. Prior to joining the biopharma industry, Dr. Myint practiced medicine specializing in hematological oncology and conducted clinical and laboratory research at multiple prestigious academic institutions in the U.K. and U.S. including Rush University Medical Center in Chicago and University of Colorado, Denver. Dr. Myint, professor of medicine, built a FACT-accredited and Center of Excellence-Designated Stem Cell Transplant Program at the University of Colorado, Denver.